

Press Release



ASKA Achieves Score of B in Climate Change, B- in Water Security, and C in Forests at CDP2025

TOKYO, December 17, 2025 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”) is pleased to announce that it has achieved a B score in Climate Change, a B- score in Water Security, and a C score in Forests at CDP2025.



CDP is a non-profit organization that operates the world's only independent environmental information disclosure system, and many companies, financial institutions, and local governments use CDP's system to manage their environmental impact. CDP evaluates the data reported by the organizations that disclose information using its own methods and scores it on an eight-point scale (A, A-, B, B-, C, C-, D, D-).

Reference: In CDP2024, more than 24,800 companies around the world responded, and more than 2,100 Japanese companies, including more than 70% of prime market listed companies, are said to have disclosed information.

The “B” and “B-” scores indicate that an organization has been evaluated as having a management level that understands and takes action regarding its environmental risks and impacts. The “C” score indicates that an organization has been evaluated as having an awareness level, which measures the comprehensiveness of its evaluation of how environmental issues intersect with its business.

ASKA aims to become a “Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company” in its Medium-Term Management Plan 2025. On the environmental front, ASKA recognizes global climate change as a management issue that will impact its business and is actively working to address it.

ASKA views this evaluation as recognition that the Group's efforts to address climate change align well with societal expectations, and it will continue to pursue sustainability initiatives, including further decarbonization.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp